In 2024, Astellas Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Astellas Pharma has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 52,212a | 59,203a | 61,171a | |
Total Scope 2 | ||||
Market-Based | 55,621a | 63,047a | 56,473a | |
Location-Based | N/A | N/A | N/A | |
Total Scope 3 | 1,276,323a | 1,121,350a | 893,617a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.9306a | 5.1928a | 5.7586a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Astellas Pharma amounted to 107,833 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Astellas Pharma decreased by 11.79%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Astellas Pharma were 52,212 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Astellas Pharma's Scope 1 emissions have decreased by 26.36%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Astellas Pharma's Scope 1 emissions decreased by 11.81%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Astellas Pharma reported Scope 2 greenhouse gas (GHG) emissions of 55,621 tCO₂e using the market-based method.a
Since 2019, Astellas Pharma's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 41.6%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Astellas Pharma's Scope 2 emissions (Market-Based) fell by 11.78% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2024, Astellas Pharma reported its Scope 2 emissions using the market-based method.a
In 2024, Astellas Pharma reported 1,276,323 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Astellas Pharma includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Astellas Pharma reported total Scope 3 emissions of 1,276,323 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.72% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.28% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Astellas Pharma's Scope 3 emissions have increased by 455.04%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Astellas Pharma's Scope 3 emissions increased by 13.82%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2024, Astellas Pharma reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Astellas Pharma's Scope 3 emissions were:a
In 2024, Astellas Pharma reported Scope 1 greenhouse gas (GHG) emissions of 52,212 tCO₂e and total revenues of USD 10,589 millions. This translates into an emissions intensity of 4.93 tCO₂e per millions USD.a
In 2024, Astellas Pharma reported a Scope 1 emissions intensity of 4.93 tCO₂e per millions USD. Compared to the peer group median of 5.5, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Astellas Pharma ranked 11 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Astellas Pharma is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Astellas Pharma reported a total carbon footprint of 1,384,156 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 11.3% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Astellas Pharma's total carbon footprint was Scope 3 emissions, accounting for 92.21% of the company's total carbon footprint, followed by Scope 2 emissions at 4.02%.a